Paper of the Month - June, 2010

0 rating

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era



READER POLL

L&L poll 2
What do you consider to be the most exciting advances in therapeutics research in myeloid leukemia at present?






Powered by NetPolls

SUBMIT AN ARTICLE